Videos

Douglas D. Koch, MD, and Karolinne Maia Rocha, MD, PhD, discuss the optics behind enhanced monofocal lenses, patient selection, and how to set expectations.

New data show 8 mg aflibercept dries retinal fluid faster and lasts longer, enabling 12–16 week dosing in AMD, DME, and RVO.

Learn why newer anti‑VEGF options extend treatment for wet AMD, DME and RVO, signaling a shift from VEGF-only to multitarget therapy.

Host Deborah Ristvedt, DO, welcomes Vance Thompson, MD, to discuss how prioritizing people has shaped the culture and growth of Vance Thompson Vision.

Experts weigh vision-first goals in retinal disease, debating dry OCT vs stable fluid, longer anti‑VEGF intervals, and next‑gen durable therapies.

Experts discuss balancing vision, dry retina goals, fluid tolerance, and longer-lasting anti-VEGF options to cut injection burden.

NYU Langone’s Jordan Mandell, MD, and Ariana Levin, MD, sit down with UCLA’s Anne Coleman, MD, to discuss her recent study on cardiovascular risk scores and their association with glaucoma, AMD, and other ocular diseases.

Andrew G. Lee, MD, and Drew Carey, MD, discuss recurrence of papilledema after discontinuation of GLP-1 receptor agonists and the implications for monitoring patients with idiopathic intracranial hypertension.

In this episode, “Diagnostic Imaging in Retinal Vascular Disease Management,” the panelists explore how recent innovations in multimodal imaging are transforming the diagnosis and management of retinal vascular diseases, including AMD, diabetic macular edema (DME), diabetic retinopathy (DR), and retinal vein occlusion (RVO). The expert faculty discuss the growing role of optical coherence tomography (OCT) as the foundational imaging modality in retina clinics and how additional technologies such as fundus autofluorescence, OCT angiography (OCTA), and ultra-widefield imaging are expanding clinicians’ ability to detect and monitor disease activity.

Ultra-widefield pediatric retinal scans plus adaptable AI reveal hidden eye issues during routine visits, enabling comfortable, scalable screening and earlier specialist referrals.

Caveolin‑1 is a membrane-associated protein expressed in many cell types that plays a key role in modulating inflammatory signaling.

Jay Chhablani, MD, a retina specialist from UPMC Vision Institute and director of the Choroidal Analysis and Research Lab at the University of Pittsburgh, discussed recent advancements in choroidal imaging.

Uveitis expert Nisha Acharya, recipient of ARVO’s Mildred Weisenfeld Award, discusses how clinical trials and big data are reshaping treatment, vaccination, and vision outcomes.

Paul Nderitu discusses Global RETFound, a diverse, worldwide retinal AI model that outperforms existing tools and sets a new standard for equitable, open-access medical AI.

NYU researchers discuss using CellChek C widefield specular microscopy to visualize and quantify corneal nerves in dry eye disease, revealing reduced nerve fiber length and inferior whorl changes and offering a practical alternative to in vivo confocal imaging.

At ARVO Michael Siatkowski, MD, and Jody Summers, PhD, stopped to discuss the rising rates of myopia in children and if anti-inflammatory drugs could play a role in slowing progression.

Single-shot optogenetic injection restores light sensitivity in advanced retinitis pigmentosa, delivering sustained vision gains for years with strong safety, expanding hope beyond gene-specific therapy.

Aaron Lee, MD, and Cecilia Lee, MD, co-recipients of this year's Cogan Award at ARVO, reflect on what the award lecture means to them and their careers.

Dimitra Skondra, MD, PhD, discussed her talk on how the diet and gut microbiome can affect the development of age-related macular degeneration.

AI-assisted screening in glaucoma clinics flags patient distress early, improving adherence and outcomes without adding staff burden.

Ariel Ong, a fellow from University College London, discussed her ARVO poster, looking at her work on developing a scalable pipeline for data extraction from ophthalmic clinical letters and what significance that could have in managing patients.

Madhura Tamhankar, MD, took some time at the ARVO conference in Denver, Colorado, to discuss a poster on disease progression in thyroid eye disease, stressing what we know about the Rundle Curve may not be accurate.

The poster looked into the LLM's potential for biases in gender and race when it came to its knowledge of retinitis pigmentosa.

Srinivas Sadda, MD, FARVO, immediate past president of ARVO, discusses the impact the organization has had on his career and how he wants to help the next generation.

Kaden Bunch, a fourth-year medical student from the Warren Alpert Medical School of Brown University, talked about his poster on large language models and the effectiveness of diagnosing red eye diseases.

At this year's ARVO meeting in Denver, Colorado, Giulia Corradetti spoke on how baseline OCT biomarkers can predict anatomic response in neovascular age-related macular degeneration when treated with faricimab.

Andrew G. Lee, MD, and Drew Carey, MD, discuss how eye and brain vascular events such as retinal vein occlusion and stroke can signal antiphospholipid syndrome and require further evaluation.

Dr. Khanani reviews 52-week safety outcomes, noting Axpaxli was generally well tolerated with no cases of endophthalmitis or retinal vasculitis.